On October 5, 2016, Alnylam announced its decision to stop its revusiran development, an investigational RNA interference therapeutic being for the treatment of hereditary ATTR amyloidosis with cardiomyopathy, naming patient safety concerns. The Data Monitoring Committee of the study informed Alnylam that the benefit-risk profile for revusiran did not support continued dosing. Following this news, Alnylam stock has dropped as much $33.00 per share, or 47.01%, to $37.24 during intraday trading on October 6, 2016.
If you are aware of any facts relating to this investigation, or if you purchased shares of Alnylam, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/alny or by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-alnylam-pharmaceuticals-inc-alny-300340861.html
SOURCE Bronstein, Gewirtz & Grossman, LLC